WILEX will publish the financial results and the Annual Report 2013 on March 31, 2014

ENGLISH DEUTSCH
PDF Download back

Munich, Germany, 25 March 2014. WILEX AG (ISIN DE0006614720 / WL6 / FWB) will publish the financial results and the Annual Report for the financial year 2013
(1 December 2012 – 30 November 2013) on March 31, 2014. On this day a public conference call for media, analysts and investors in English will take place at 03:00 p.m. CET.

Please dial in ten minutes before the conference call using the following dial-in numbers:

1. Germany: +49 69 71044 5598
2. UK: +44 20 3003 2666
3. USA: +1 212 999 6659
4. USA Freephone: +1 866 966 5335

You will be welcomed by an operator who will ask for the password (WILEX) and take your name and company. The presentation for the conference will be available for download from www.wilex.com from 02:30 p.m. CET.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany. Focused on oncology, the Company develops diagnostic and therapeutic product candidates based on antibodies and small molecules, which are available for out-licensing. The subsidiary Heidelberg Pharma GmbH offers preclinical contract research services and an antibody drug conjugate (ADC) technology platform. Our customers and partners include leading international pharmaceutical companies. WILEX AG is listed at the Frankfurt Stock Exchange. ISIN DE0006614720 / WKN 661472 / Symbol WL6. More information is available at www.wilex.com.

Contact
WILEX AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
E-Mail: investors[at]wilex.com
Grillparzerstr. 10, 81675 München
For press enquiries
MC Services AG
Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-126
Tel.: +49-89-210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu 
Seite gelesen: 356 | Heute: 5